ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
Source: SeekingAlpha
2025-12-03 10:53:25 ET
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL December 3, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript
ADC Therapeutics SA
NASDAQ: ADCT
ADCT Trading
-5.62% G/L:
$4.20 Last:
295,591 Volume:
$4.36 Open:
ADCT Latest News
March 10, 2026 07:30:00 am
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
ADCT Stock Data
$486,217,661
104,923,913
12.45%
40
N/A
Biotechnology & Life Sciences
Healthcare
CH
Epalinges
